Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain an average rating of Moderate Buy on Sutro Biopharma from 13 brokerages, with a 1‑year average price target of about $40.78 and recent upgrades from firms including Truist and Lifesci to Strong‑Buy.
• The stock trades near its 52‑week high (opened $37.69) with a market cap of $624.5M, but the company is unprofitable (PE -1.44) and analysts forecast continued multi‑year net losses, signaling material cash‑burn and clinical‑development risk.
• Institutional ownership is very high (about 96.99%), and several funds — including Invesco, Bridgeway, Cerity, Qube and the Tennessee Treasury — have recently added or boosted positions.

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has received an average rating of "Moderate Buy" from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $40.7778.

A number of equities analysts have weighed in on the company. Leerink Partners assumed coverage on Sutro Biopharma in a report on Tuesday, April 7th. They issued an "outperform" rating and a $38.00 price target for the company. Wall Street Zen upgraded Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Lifesci Capital upgraded Sutro Biopharma to a "strong-buy" rating in a report on Friday, May 1st. Truist Financial upgraded Sutro Biopharma to a "strong-buy" rating in a report on Monday. Finally, HC Wainwright upgraded Sutro Biopharma from a "neutral" rating to a "buy" rating and upped their price target for the stock from $10.00 to $28.00 in a report on Tuesday, March 24th.

Sutro Biopharma Stock Performance

STRO opened at $37.69 on Thursday. The company has a market cap of $624.52 million, a PE ratio of -1.44 and a beta of 1.63. Sutro Biopharma has a 1 year low of $6.74 and a 1 year high of $39.74. The firm has a 50 day moving average price of $26.50 and a 200 day moving average price of $16.93.

Key Stories Impacting Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Truist upgraded Sutro to a "Strong-Buy", providing a clear buy-side catalyst that likely boosted investor demand. Zacks
• Positive Sentiment: Lifesci Capital reiterated a "Strong-Buy" stance on STRO and published refreshed analyst coverage, which supports continued bullish sentiment among institutional and retail investors. MarketBeat
• Neutral Sentiment: Lifesci released a full set of quarterly and multi-year EPS projections for STRO (Q1–Q4 2026, FY2026–FY2030 and interim 2027–2029 quarters). These updates provide additional modeling detail for investors but do not by themselves change company fundamentals. MarketBeat
• Negative Sentiment: The Lifesci model projects continued material net losses across multiple years (examples: FY2026 ≈ -$6.60/share; FY2027 ≈ -$5.45/share; Lifesci/consensus FY current-year around -$9.17). Those persistent negative EPS forecasts highlight ongoing cash-burn/clinical-development risk, which could pressure valuations if clinical or partnership news lags. MarketBeat

Hedge Funds Weigh In On Sutro Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of STRO. Bridgeway Capital Management LLC boosted its stake in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock valued at $37,000 after buying an additional 30,000 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Sutro Biopharma by 137.8% during the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company's stock valued at $60,000 after buying an additional 53,390 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Sutro Biopharma by 169.9% during the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company's stock valued at $75,000 after buying an additional 66,372 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Sutro Biopharma during the 2nd quarter valued at approximately $82,000. Finally, State of Tennessee Department of Treasury purchased a new position in shares of Sutro Biopharma during the 4th quarter valued at approximately $86,000. Hedge funds and other institutional investors own 96.99% of the company's stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.